260 related articles for article (PubMed ID: 30504300)
21. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S
Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878
[TBL] [Abstract][Full Text] [Related]
22. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
23. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
[TBL] [Abstract][Full Text] [Related]
24. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
25. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
Harrison CN; Talpaz M; Mead AJ
Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
[TBL] [Abstract][Full Text] [Related]
26. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
27. Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry.
Góra-Tybor J; Gołos A; Mikulski D; Helbig G; Sacha T; Lewandowski K; Niesiobędzka-Krężel J; Bieniaszewska M; Wysogląd H; Grzybowska-Izydorczyk O; Seferyńska I; Sobas M; Czyżewska M; Michalska A; Sawicki W; Mazur M; Hus M; Bodzenta E; Olszewska-Szopa M; Włodarczyk M; Patkowska E; Świstek W; Jamroziak K
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e19-e26. PubMed ID: 36396583
[TBL] [Abstract][Full Text] [Related]
28. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
Chifotides HT; Masarova L; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):219-231. PubMed ID: 36797153
[TBL] [Abstract][Full Text] [Related]
29. [What's new in myeloproliferative neoplasia?].
Schmidt S; Wolf D
Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
31. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
Xu ZF; Qin TJ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):24-28. PubMed ID: 30704224
[No Abstract] [Full Text] [Related]
32. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review.
Marchetti M
Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):469-480. PubMed ID: 28796569
[TBL] [Abstract][Full Text] [Related]
33. Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to.
Li Y; Zhu S; Liu W; Ming J; Wang X; Hu X
Ann Hematol; 2020 Jun; 99(6):1161-1176. PubMed ID: 32333155
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
[TBL] [Abstract][Full Text] [Related]
35. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.
Kuykendall AT; Shah S; Talati C; Al Ali N; Sweet K; Padron E; Sallman DA; Lancet JE; List AF; Zuckerman KS; Komrokji RS
Ann Hematol; 2018 Mar; 97(3):435-441. PubMed ID: 29189896
[TBL] [Abstract][Full Text] [Related]
36. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
37. Rationale for combination therapy in myelofibrosis.
Mascarenhas J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
[TBL] [Abstract][Full Text] [Related]
38. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
[TBL] [Abstract][Full Text] [Related]
39. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
[TBL] [Abstract][Full Text] [Related]
40. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Mesa RA; Verstovsek S; Cervantes F; Barosi G; Reilly JT; Dupriez B; Levine R; Le Bousse-Kerdiles MC; Wadleigh M; Campbell PJ; Silver RT; Vannucchi AM; Deeg HJ; Gisslinger H; Thomas D; Odenike O; Solberg LA; Gotlib J; Hexner E; Nimer SD; Kantarjian H; Orazi A; Vardiman JW; Thiele J; Tefferi A;
Leuk Res; 2007 Jun; 31(6):737-40. PubMed ID: 17210175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
